ASX Share rice
Wed 21 Oct 2020 - 10:09:pm (Sydney)

ZLD Share Price

ZELIRA THERAPEUTICS LIMITEDZLDPharmaceuticals, Biotechnology & Life Sciences

ZLD Company Information

Name:

Zelira Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

140 St George's Terrace Perth WA Australia 6000

Phone:

61 8 6558 0886

Founder & Chairman:

Mr. Osagie O. Imasogie

MD & Director:

Dr. Richard Miles Hopkins

Co-Founder & Non-Exec. Deputy Chairman:

Mr. Harry Karelis B.Sc (Hons), MBA, CFA, F.Fin, FAICD

Co-Founder & Non-Exec. Director:

Mr. Jason William Peterson

CEO of USA, MD of USA & Director:

Dr. Oludare Odumosu

Company Overview:

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.

ZLD Share Price Information

Shares Issued:

1.19B

Market Capitalisation:

$94.83M

Revenue (TTM):

$0.98M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.005

Operating Margin (TTM):

$-6.88

Return On Assets (TTM):

$-0.22

Return On Equity (TTM):

$-0.37

Quarterly Revenue Growth (YOY):

-0.934

Gross Profit(TTM):

$0.98M

Diluted Earnings Per Share (TTM):

$-0.008

ZLD CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$1.11M

Change To Liabilities:

$-50,111

Total Cashflow From Investing Activities:

$1.11M

Net Income:

$-7,015,045

Total Cash From Operating Activities:

$-6,936,280

Other Cashflow From Investing Activities:

$1.12M

Sale Purchase Of Stock:

$4.79M

Capital Expenditures:

$15.97K

ZLD Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-7,015,050

Net Income:

$-7,015,050

Operating Income:

$-6,896,410

Other Operating Expenses:

$98.28K

Interest Expense:

$12.34K

Total Revenue:

$1.04M

ZLD Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$1.28M

Total Liabilities:

$1.24M

Total Stockholder Equity:

$34.55M

Other Current Liabilities:

$50K

Total Assets:

$35.79M

Common Stock:

$26.08M

Other Current Assets:

$1.10K

Retained Earnings:

$8.58M

Good Will:

$30.75M

Cash:

$1.70M

Total Current Liabilities:

$670.25K

Property - Plant & Equipment:

$1.58M

Net Tangible Assets:

$2.52M

Long-Term Investments:

$350.35K

Total Current Assets:

$1.83M

Net Receivables:

$64.14K

Short-Term Investments:

$33.96M

Accounts Payable:

$559.39K

Short-Term Investments:

$33.96

Non Current Liabilities Total:

$571.46K

ZLD Share Price History

ZLD News

22 Jul, 2020
Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding agreement with US-based Cardiovascular Solutions of Central Mississippi to develop products that target symptoms and health risks related to cardiovascular disease and diabetes. According to the Agreement, Zelira will develop exclusively for CVSCM novel, hemp-derived formulations of CBD and other cannabinoids to address a range of therapeutic needs associated with Peripheral Arterial Disease (PAD) and Diabetic Neuropathies (DPN).
08 May, 2020
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...
08 Apr, 2020
Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF), a global leader in the development of clinically validated cannabis medicines based in both Perth, Australia and Philadelphia, is pleased to announce it has received the final report for its ZTL-101 medicinal cannabis trial for insomnia. Its findings represent a world-first clinical validation demonstrating that ZTL-101 cannabis treatment is safe and effective for chronic insomnia. These results open prospects to launch and distribute this product in global markets including the USA in the second half of 2020.
19 Feb, 2020
28 Jan, 2020
Zelira Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF) is pleased to announce a collaboration with the Parkinson's Foundation, one of the United States of America's leading communities for people living with Parkinson's disease (PD), to gather insights from people with PD about their understanding of and use of medical cannabis and hemp-derived therapies. In 2019, Zelira Therapeutics participated in the Medical Cannabis Conference organized by the Parkinson's Foundation, and is now assisting in the development of a survey to understand the current use and perceived benefits of medical cannabis among people with PD. This collaboration combines the Foundation's understanding of the underlying science of Parkinson's disease and the most prevalent symptoms impacting people with the disease with Zelira Therapeutics' extensive experience in pharmaceutical and condition-specific medical cannabis product development.
03 Dec, 2019
Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF, Zelira), formerly Zelda Therapeutics Ltd, announced today it will bring its HOPE® Franchise to the state of Louisiana with a licensing agreement that will generate immediate revenue through a licensing arrangement which includes an up-front fee and ongoing royalties. The commercial terms of this arrangement remain confidential. The Franchise was launched successfully in Pennsylvania in May 2019 under Ilera Healthcare which holds the license for the state. Since entering the market, HOPE® has shown strong revenue growth establishing itself as the top selling formulated medicinal cannabis product line in Pennsylvania.
05 Nov, 2019
A look at the shareholders of Zelda Therapeutics Limited (ASX:ZLD) can tell us which group is most powerful. Large...